2022
Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings
Mulamba C, Williams C, Kreppel K, Ouedraogo J, Olotu A. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria Journal 2022, 21: 159. PMID: 35655174, PMCID: PMC9161629, DOI: 10.1186/s12936-022-04173-y.Peer-Reviewed Original ResearchConceptsEndemic settingsMalaria transmission-blocking vaccineHuman vaccine trialsTransmission-blocking vaccinesPublic health importanceMosquito vectorsMiddle-income settingsAnti-malarial drugsImmunological mechanismsCandidate vaccinesVaccine trialsHealthy individualsIncome settingsTransmission blockingHealth importanceMalaria controlMalaria parasitesVaccineLocal interventionsDrugsInterventionSettingSexual stagesPfs25Disease
2013
Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds
Da D, Dixit S, Sattabonkot J, Mu J, Abate L, Ramineni B, Ouedraogo J, MacDonald N, Fay M, Su X, Cohuet A, Wu Y. Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds. Infection And Immunity 2013, 81: 1984-1989. PMID: 23509152, PMCID: PMC3676035, DOI: 10.1128/iai.00016-13.Peer-Reviewed Original ResearchConceptsPhase 1 trialParasite isolatesMalaria transmission-blocking vaccineTransmission-reducing activityTransmission-blocking activityPlasmodium falciparum isolatesTransmission-blocking vaccinesPlasmodium falciparum parasitesLimited sequence polymorphismPfs25 antibodiesMontanide ISA51Immune plasmaNonimmune controlsRecombinant Pfs25Falciparum isolatesPfs25 geneFalciparum parasitesGenetic backgroundPatientsBurkina FasoPfs25VaccineTrialsNucleotide polymorphismsIsolates